Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial

 

• MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs placebo
• Improvements observed across key symptoms, including nausea, early satiety, post-prandial fullness and upper abdominal pain
• Favorable safety and tolerability profiles
• Late-breaking oral presentation delivered at Digestive Disease Week (DDW) 2026 in Chicago, IL

FREIBURG, Germany and ROSCREA, Ireland, May 5 (Bernama-GLOBE NEWSWIRE) -- Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), a research-based pharmaceutical company specializing in digestive and metabolic medicine, and Renexxion Ireland Limited (“Renexxion”), a clinical-stage biopharmaceutical company, today announced positive results from MOVE-IT (NCT05621811), a global Phase 2b, randomized placebo-controlled trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesis. 

The double-blind, multicenter, 12-week study enrolled 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis symptoms and objective evidence of delayed gastric emptying. Eligible patients received either 10 mg, 20 mg, 40 mg naronapride, or placebo, administered orally three times a day (TID) for 12 weeks.  

MOVE-IT met the primary endpoint, demonstrating statistically significant improvement versus placebo in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index Daily Diary (ANMS GCSI-DD) Core Symptom Score in the 20 mg TID (p=0.0046) and 40 mg TID (p=0.0156) groups. The ANMS GCSI-DD is a content-validated, patient-reported outcome instrument that assesses the five cardinal gastroparesis symptoms: nausea, vomiting, early satiety, postprandial fullness and upper abdominal pain.

Table 1. Primary endpoint – Change from baseline to Week 12 in the average weekly ANMS GCSI-DD Core Symptom Score

			Naronapride  10 mg TID	Naronapride 20 mg TID	Naronapride 40 mg TID	Placebo TID
Total Population			N=83	N=80	N=80	N=85
Baseline (BSL) Week 12	Mean (SD) Mean (SD)		2.450 (0.388) 1.155 (0.797)	2.429 (0.341) 0.883 (0.759)	2.462 (0.450) 0.907 (0.780)	2.402 (0.396) 1.280 (0.911)
Change to Week 12	LS Mean (SE)  +/- 95% CI		-1.244 (0.100)  [-1.440, -1.048]	-1.512 (0.102)  [-1.712, -1.311]	-1.452 (0.100)  [-1.649, -1.256]	-1.106 (0.095)  [-1.293, -0.920]
Difference to Placebo	LS Mean (SE)		-0.138 (0.136)	-0.405 (0.137)	-0.346 (0.136)
Dunnett-Hsu Adjusted	97.5%-CI  p-value†		[-∞, 0.183]  0.3112	[-∞, -0.081]  0.0046	[-∞, -0.024]  0.0156

_{CI = Confidence interval; LS Means = Least square means; N = Number of participants in analysis population; SD = Standard deviation; SE = Standard error. † One-sided}

Naronapride also demonstrated statistically significant improvements versus placebo from baseline to Week 12 across key secondary and exploratory endpoints in the total population:

• ANMS GCSI-DD Composite Score (core score excluding vomiting): Statistically significant improvements observed in 20 mg (p=0.0024) and 40 mg (p=0.0117) TID dose groups versus placebo.
• Responder Analyses: Approximately 15-20% more participants achieved clinically meaningful improvement (defined as >1.0 decrease in ANMS GCSI-DD Composite Score) with naronapride 20 mg or 40 mg TID vs. placebo, with no added benefit of 40 mg over 20 mg.  
• Patient-Reported Quality of Life (QoL): Global improvements reflecting meaningful benefit beyond core symptom reduction and supporting consistency of treatment effect across validated symptom assessment instruments.
• Improvement in gastric emptying breath test (GEBT): All active doses achieved greater gastric emptying versus placebo. Maximum improvement with 20 mg (mean -21.95 minutes) and 40 mg (mean –14.92 minutes) versus placebo (mean –10.96 minutes).

Consistent with previous studies, the safety and tolerability profiles were favorable, with no new safety signals identified versus placebo, including cardiac, neuropsychiatric, or prolactin-related signals. To date, naronapride has been studied in over 1200 subjects, with a safety profile reflecting its minimal systemic absorption. 

Dr. Kai Pinkernell, M.D., Managing Director Science & Innovation at Dr. Falk Pharma, commented: “We are excited about the outcomes showing a significant and clinically meaningful impact on gastroparesis symptoms, all combined with a favorable safety profile. This is an important step towards providing physicians and patients with a treatment option where few effective choices exist. We look forward to sharing these results with the scientific community, engaging with regulatory authorities, and moving decisively toward registration studies later this year and eventual commercialization.” 

Dr. Peter Milner, M.D., FACC, Chairman and CEO of Renexxion, commented: “These Phase 2b results represent a significant milestone for the naronapride program, demonstrating statistically significant improvement in gastroparesis symptoms with a favorable safety and tolerability profile. We believe naronapride’s locally acting, dual mechanism pharmacology and safety-by-design profile position it as a potential best-in-class therapy for gastroparesis, a disease with significant unmet medical need and limited, safe, effective long-term treatment options. Together with our partner Dr. Falk Pharma, we are now focused on advancing naronapride into late-stage development with the goal of bringing an important new treatment option to physicians and patients.”

About Naronapride
Naronapride is a potential best-in-class oral, locally acting pan-GI prokinetic designed to enhance coordinated motility across the digestive tract. Naronapride works through a differentiated dual mechanism of action- 5-HT4 receptor agonism and dopamine D2 receptor antagonism- modulating two validated targets on the luminal surface of the intestinal wall that regulate GI motility and nausea signaling.  Naronapride’s dual pharmacology, minimal systemic bioavailability, and differentiated pharmaceutical and pharmacokinetic profile are designed to deliver targeted activity within the GI tract while limiting systemic exposure. To date, naronapride has demonstrated a favorable safety and tolerability profile across nine Phase 1 clinical trials and five Phase 2 clinical trials conducted in multiple indications including gastroesophageal reflux disease, erosive esophagitis and chronic idiopathic constipation.

About Gastroparesis
Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying and debilitating symptoms including nausea, vomiting, early satiety, upper abdominal pain and postprandial fullness. Approximately 22 per 100,000 individuals across US and Europe are formally diagnosed with gastroparesis, while up to 12-times more experience symptoms consistent with the disease. Despite the substantial disease burden, the availability of safe and effective long‑term treatment options remains limited.

About Renexxion
Renexxion Ireland Limited, a wholly-owned Irish subsidiary of California-based Renexxion, Inc., is a privately held biopharmaceutical company committed to developing new therapies for patients with gastrointestinal disorders. Renexxion’s lead program is naronapride, a late-stage drug candidate being developed for multiple unmet indications in the upper and lower GI tract.

Further information on Renexxion can be found online: https://www.rnexltd.ie

Media Inquiries:   
Press@rnexltd.ie
+353 61 539121

About Dr. Falk Pharma GmbH  
Dr. Falk Pharma GmbH has been developing and marketing innovative medicines to treat a wide range of gastrointestinal disorders like inflammatory bowel disease or eosinophilic esophagitis as well as hepatobiliary disorders such as primary biliary cholangitis for over 60 years. As the international experts in digestive and metabolic medicine, the company brings together physicians, scientists, and patients to devise new and powerful approaches to patient care. Dr. Falk Pharma engages in pre-clinical and clinical stage research that aims to meaningfully improve therapeutic practice as well as patient health and well-being. A family-owned business with a global presence, Dr. Falk Pharma has ten affiliates in Europe and Australia and is continuously growing. The company has its headquarters and R&D facilities in Freiburg, Germany, its pharmaceutical products are manufactured in Europe, mainly at sites in Germany, France, Italy, and Switzerland. Falk employs approximately 1,550 individuals globally and 450 in Freiburg.

Further information on Dr. Falk Pharma can be found online: https://drfalkpharma.com 

SOURCE: Dr. Falk Pharma

MELTWATER, YOUGOV REPORT HIGHLIGHTS SHIFTING CONSUMER TRUST IN AI-GENERATED CONTENT

KUALA LUMPUR, April 22 (Bernama) -- Meltwater and YouGov have released Trust in the Age of Generative AI, a new report exploring how the rapid rise of artificial intelligence (AI)-generated video, audio, images and text is shaping consumer trust in brands and content.

Drawing insights from nearly 10,000 consumers across seven global markets, the study examines attitudes toward generative AI (GenAI) and the media environments that influence these perceptions. The findings offer key insights for brands navigating this rapidly evolving landscape.

Meltwater Chief Product Officer, Chris Hackney in a statement said GenAI provides brands with a powerful new way to connect with audiences, but success depends on how transparently and thoughtfully it is used, and brands that lead with clarity and accountability have a real opportunity to build deeper trust.

As GenAI becomes more integrated into marketing and communications, the report reveals a pivotal moment for brands, not only in how they adopt AI, but also in how they redefine trust-building with audiences.

The findings also point to a meaningful opportunity, in which consumers want brands to be transparent, intentional, and audience-first in their use of AI, and those that are could differentiate themselves and build stronger, more trusted relationships with their audiences.

The report finds that transparency is a critical factor, with 86 per cent of consumers saying AI-generated content should be disclosed, presenting a clear opportunity for brands to build trust.

At the same time, perceptions remain mixed, as 32 per cent of respondents say they would trust brands less if content is AI-generated, compared with 15 per cent who would trust them more, underscoring the importance of how AI is applied and communicated.

Consumer sentiment toward AI also reflects a degree of caution, with 39 per cent expressing excitement while a larger 51 per cent remain unconvinced. Awareness is increasing, as 58 per cent of consumers believe they can identify AI-generated content, while online discussions have grown by 53 per cent, with media contributing 34 per cent of overall coverage.

Concerns over misinformation remain high, with 73 per cent of respondents highlighting it as a key issue, creating an opening for brands to position themselves as reliable and trustworthy sources. Acceptance of AI varies by context, with higher levels seen in entertainment and advertising, but significantly lower trust in news and influencer content.

“These insights show that trust is not being lost; it is being redefined,” added Hackney.

-- BERNAMA

MELTWATER, YOUGOV REPORT HIGHLIGHTS SHIFTING CONSUMER TRUST IN AI-GENERATED CONTENT

EZE Cloud Goes Live on Workday.

KUALA LUMPUR, April 22 (Bernama) -- Meltwater and YouGov have released Trust in the Age of Generative AI, a new report exploring how the rapid rise of artificial intelligence (AI)-generated video, audio, images and text is shaping consumer trust in brands and content.

Drawing insights from nearly 10,000 consumers across seven global markets, the study examines attitudes toward generative AI (GenAI) and the media environments that influence these perceptions. The findings offer key insights for brands navigating this rapidly evolving landscape.

Meltwater Chief Product Officer, Chris Hackney in a statement said GenAI provides brands with a powerful new way to connect with audiences, but success depends on how transparently and thoughtfully it is used, and brands that lead with clarity and accountability have a real opportunity to build deeper trust.

As GenAI becomes more integrated into marketing and communications, the report reveals a pivotal moment for brands, not only in how they adopt AI, but also in how they redefine trust-building with audiences.

The findings also point to a meaningful opportunity, in which consumers want brands to be transparent, intentional, and audience-first in their use of AI, and those that are could differentiate themselves and build stronger, more trusted relationships with their audiences.

The report finds that transparency is a critical factor, with 86 per cent of consumers saying AI-generated content should be disclosed, presenting a clear opportunity for brands to build trust.

At the same time, perceptions remain mixed, as 32 per cent of respondents say they would trust brands less if content is AI-generated, compared with 15 per cent who would trust them more, underscoring the importance of how AI is applied and communicated.

Consumer sentiment toward AI also reflects a degree of caution, with 39 per cent expressing excitement while a larger 51 per cent remain unconvinced. Awareness is increasing, as 58 per cent of consumers believe they can identify AI-generated content, while online discussions have grown by 53 per cent, with media contributing 34 per cent of overall coverage.

Concerns over misinformation remain high, with 73 per cent of respondents highlighting it as a key issue, creating an opening for brands to position themselves as reliable and trustworthy sources. Acceptance of AI varies by context, with higher levels seen in entertainment and advertising, but significantly lower trust in news and influencer content.

“These insights show that trust is not being lost; it is being redefined,” added Hackney.

-- BERNAMA

Vocalbeats.AI Brings AI Note-Taking to the Wrist with Apple Watch Experience for Owll

 

SINGAPORE, April 22 (Bernama-GLOBE NEWSWIRE) -- Vocalbeats.AI, a Singapore-based AI-powered audio company, recently launched a major update to its smart productivity app, Owll, introducing a purpose-built Apple Watch experience.

This update marks a key milestone for Owll, extending its voice-first productivity experience directly to the wrist and into real-time, everyday use cases. With a dedicated Apple Watch app, users can instantly capture ideas, meeting notes, and conversations with a single tap—enabling them to remain present and fully engaged without the friction of reaching for a device.

Owll for Apple Watch introduces intuitive, wrist-based recording designed for users demanding agility:

• One-tap activation: Instantly capture meeting notes, voice memos, and actionable ideas with a single tap.
• Hands-free experience: Record effortlessly during live conversations or while in transit.
• Cross-device synchronization: Automatically sync recordings in real time across the Apple ecosystem, including Apple Watch, iPhone, iPad, and web interfaces.
   

Traditional note-taking often disrupts attention, requiring multiple steps before a recording can begin. By migrating capture capabilities to the wrist, Owll reduces friction to a single tap, enabling users to record discreetly and capture information efficiently without breaking their workflow. Designed with simplicity and accessibility in mind, Owll reflects Vocalbeats.AI’s human-centric approach, focusing on practical innovation that makes voice interaction more intuitive and inclusive across everyday use cases.

AI-Driven Summaries and Apple Ecosystem Integration

Beyond basic transcription, Owll’s AI transforms unstructured audio content into structured summaries, key insights, and actionable follow-ups, streamlining the end-to-end workflow from initial capture to final output.

Seamless integration across Apple devices ensures users can review, organize, and execute on insights immediately upon saving.

Capitalizing on Growing Global Demand for Voice-First Productivity

This latest update builds upon Owll’s accelerating global traction. According to January 2026 data from Sensor Tower, Owll ranked #1 in the Utilities category in two countries and within the top 10 highest-grossing Utilities apps across 26 countries—pointing to growing market demand for voice-first productivity solutions that integrate seamlessly into daily workflows.

Building on this momentum, Vocalbeats.AI continues to expand Owll’s ecosystem to meet the evolving needs of users worldwide.

Download the App

Users can install Owll on their Apple Watch by downloading the companion app on the Apple App Store for their iPhone and following the automated pairing prompts. Once installed, audio capture starts with a single tap, and saved recordings synchronize seamlessly across all connected devices.

The latest version of Owll is now available on the Apple App Store.

About Vocalbeats.AI

Vocalbeats.AI is a Singapore-based AI-powered audio company dedicated to innovating intelligent, user-friendly products and services designed to improve everyday life with more lifelike, intuitive, and accessible voice AI. Its expanding portfolio of AI-powered applications—spanning productivity, wellness, and beyond—is increasingly being embraced by a diverse global user base.

Beyond developing applications, Vocalbeats.AI is redefining how people interact with AI. Powered by an international team of engineers, designers and researchers, the Company pushes the boundaries of voice and AI technology to empower people everywhere to work smarter, connect more meaningfully, and live better.

For more information, please visit www.vocalbeats.ai.

Media contact: media@vocalbeats.com 

SOURCE: Vocalbeats

2026 Fujian Provincial Conference on Development of Cultural, Tourism Economy opens on Apr. 17 in Zhangzhou, SE China's Fujian

 

^{​Longjiang Years Scenic Area: an urban renewal project in Hi-Tech Zone, Zhangzhou, SE China's Fujian}


ZHANGZHOU, China, Apr. 20, 2026 /Xinhua-AsiaNet/--

The 2026 Fujian Provincial Conference on the Development of Cultural and Tourism Economy kicked off in Zhangzhou, China's Fujian province on Friday. The event is themed "Building a World-Class Destination, Cultivating a Pillar Industry," highlighting elements of Minnan (Southern Fujian) wisdom, lifestyle, and culture. Coinciding with a local major initiative to build the World Minnan Cultural Exchange Center, the conference has curated 6 main activities with 60 peripheral events to attract global visitors.

The opening ceremony featured the Homing Minnan (Return to Southern Fujian) show. Set against the backdrop of the historic Yuegang Port and local craftsmanship, the show utilized interactive staging to bring the "daring to try, striving to win" spirit vividly to life.

The conference is expected to focus on industrial synergy and investment promotion, encouraging interaction among various sectors of cultural tourism industry. Projects to be launched cover the emerging performance-driven economies, sports tourism, "film-and-TV-plus-tourism," and wellness retreats.

Further celebrating regional identity, the conference is scheduled to stage Minnan cultural showcases, including comedy acts, galas, and cross-strait Gezi Opera performances. Among the highlights is the "Fresh Fujian Lifestyle" campaign, which takes the advantage of the May Day holiday and summer peak seasons to offer domestic and international guests an authentic taste of southern Fujian living.

Ever since 2023, the annual conference has been seen as a vital catalyst for boosting industry confidence and facilitating the deep integration of culture and tourism across the province.

Source: Organizing Committee of the 2026 Fujian Provincial Conference on the Development of Cultural and Tourism Economy

Horizon Quantum and AQT to Advance Real-World Quantum Applications with Strategic Hardware–Software Collaboration

By integrating Horizon’s software infrastructure with AQT’s trapped-ion quantum computing systems, this collaboration helps accelerate progress towards real-world quantum applications. 


SINGAPORE & INNSBRUCK, Austria, April 16 (Bernama-BUSINESS WIRE) -- Horizon Quantum Computing Pte. Ltd., the wholly-owned subsidiary of Horizon Quantum Holdings Ltd. (Nasdaq: HQ “Horizon Quantum”), a pioneer of software infrastructure for quantum applications, and AQT (Alpine Quantum Technologies), a leading European provider of trapped-ion quantum computers, today announced a strategic collaboration to advance the development of real-world quantum computing applications via increased hardware-software integration. By combining advanced hardware capabilities with scalable software infrastructure, the two companies aim to accelerate users’ ability to build real-world quantum applications.

The integration of Triple Alpha—Horizon Quantum's integrated development environment—with AQT's trapped-ion quantum processors—a leading modality known for high gate fidelity and low error rates—is intended to enable developers with and without specialised hardware expertise to harness the power of AQT’s systems at various levels of abstraction. Using Triple Alpha, developers can write, compile, and deploy quantum programs directly onto AQT’s processors, accessing the hardware via the cloud.

“AQT’s trapped ion systems provide low error rates and long coherence times, potentially increasing the scalability and reliability of quantum computing,” said Horizon Quantum CEO Dr Joe Fitzsimons. “Through this collaboration, Triple Alpha users will gain access to AQT’s processors, expanding their options for cutting-edge hardware designed to solve difficult computational problems.”

Horizon Quantum and AQT will engage customers as equals, working together to solve computational problems and achieve joint technical firsts in the fields of quantum computing and software development.

“The Triple Alpha software development environment navigates the diversity and complexity of today’s quantum stack, providing developers with access at multiple levels of abstraction to deliver both programming freedom and fine-grained precision,” said Dr Thomas Monz, CEO of AQT. “The collaboration with Horizon Quantum provides broad and easy access to AQT’s hardware and leverages synergies between the two companies, which share the common goal of advancing quantum computing in practice."

Horizon Quantum’s objective is to build the most capable hardware-agnostic software infrastructure. Horizon Quantum believes the collaboration with AQT is an important step towards further broadening the range of hardware architectures supported in Triple Alpha. To accelerate its research and development efforts and further advance Triple Alpha, Horizon Quantum recently listed on Nasdaq under the ticker HQ.

About Horizon Quantum

Horizon Quantum [NASDAQ: HQ] is on a mission to unlock broad quantum advantage by building the software infrastructure that empowers developers to use quantum computing to solve the world’s toughest computational problems.

Founded in 2018 by Dr Joe Fitzsimons, a leading researcher and former professor with more than two decades of experience in quantum computing, the company is bridging the gap between today’s hardware and tomorrow’s applications through the creation of advanced quantum software development tools. Its integrated development environment, Triple Alpha, enables developers to write sophisticated, hardware-agnostic quantum programs at different levels of abstraction. Learn more at www.horizonquantum.com.

About AQT

Building on decades of experience in experimental and theoretical quantum information processing in Innsbruck (Austria), AQT develops and builds quantum computers. The company offers ion trap-based quantum computers that fit seamlessly into conventional IT infrastructure and can be operated from any PC or laptop, regardless of location. AQT enables its customers to install quantum computers on site or to explore use-cases via a convenient cloud solution. Researchers and developers are supported by both quantum hardware components as well as complete systems that significantly accelerate the development of quantum solutions. Learn more at www.aqt.eu.

Note to Investors Regarding Forward-Looking Statements

This press release includes forward-looking statements. The expectations, estimates, and projections of the businesses of Horizon Quantum may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “anticipate,” “intend,” “may,” “will,” “could,” “should,” “potential,” “plan” “enable,” and similar expressions are intended to identify such forward-looking statements. Actual results may differ materially and adversely from those expressed or implied in any forward-looking statements and Horizon Quantum therefore cautions against placing undue reliance on any of these forward-looking statements. Many of these factors are outside of the control of Horizon Quantum and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) statements regarding estimates and forecasts of other financial, performance and operational metrics and projections of market opportunity; (2) references with respect to the anticipated benefits of the strategic collaboration with AQT; (3) the outcome of any efforts to integrate Horizon Quantum and AQT’s trapped-ion processor technology with Horizon Quantum’s software infrastructure; (4) Horizon Quantum’s ability to scale and grow its business, and the advantages and expected growth of Horizon Quantum; (5) the cash position of Horizon Quantum; (6) the ability to recognize the anticipated benefits of the recently completed business combination with dMY Squared Technology Group, Inc., which may be affected by, among other things, competition, the ability of Horizon Quantum to grow and manage growth profitably and source and retain its key employees; (7) costs, if any, related to the strategic collaboration with AQT; (8) changes in applicable laws and regulations or political and economic developments; (9) the possibility that Horizon Quantum may be adversely affected by other economic, business and/or competitive factors; (10) Horizon Quantum’s estimates of expenses and profitability; (11) difficulties operating Horizon Quantum’s quantum processors and the possibility that the quantum processors do not provide the advantages that Horizon Quantum expects; (12) the ability of Horizon Quantum to integrate access to its quantum computing test bed, including AQT’s technology, within its Triple Alpha platform; (13) the ability of Horizon Quantum’s coding languages to provide additional abstraction when compared to other quantum computing solutions; (14) the ability to maintain the listing of Horizon Quantum’s Class A ordinary shares and warrants on Nasdaq; and (15) other risks and uncertainties included in the “Risk Factors” sections of the Registration Statement on Form F-4 filed by Horizon Quantum in connection with the Business Combination, other documents filed or to be filed with the SEC by Horizon Quantum. The foregoing list of factors is not exclusive. New risks emerge from time to time, and it is not possible for management to predict all risks, nor can management assess the impact of all factors on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. Horizon Quantum does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20260415917591/en/

Contact

Media Contact
Horizon Quantum media contact
Yanina Blaclard
media@horizonquantum.com 

AQT media contact
Franz Domig
franz.domig@aqt.eu 

Investor Contact
Horizon Quantum investor contact
Katherine Bailon
investors@horizonquantum.com 

Source : Horizon Quantum Computing Pte. Ltd.

BRIDGE ALLIANCE EXTENDS SUMMIT TO FIVE DAYS, DRIVING GLOBAL MEDIA TRANSFORMATION

KUALA LUMPUR, April 15 (Bernama) -- BRIDGE Alliance will expand its flagship BRIDGE Summit to five days for its second edition, scheduled to take place beginning Nov 28 at a larger venue on Yas Island in Abu Dhabi, in partnership with Miral, a developer of immersive destinations and experiences in the emirate.

The expansion reflects a broader strategic shift to position BRIDGE as a year-round global platform shaping the future of media, the creative economy and cross-border collaboration.

The announcement was made during the alliance’s third board of directors meeting, by BRIDGE Alliance Chairman, Sheikh Abdulla bin Mohammed bin Butti Al Hamed, where members outlined plans to evolve BRIDGE from a high-impact gathering into a more permanent institutional platform aimed at driving long-term industry transformation.

“BRIDGE is a long-term institutional project that redefines the role of media within the equation of development, economy, and knowledge,” said Sheikh Abdulla in a statement.

Meanwhile, BRIDGE Alliance Vice Chairman, Dr Jamal Al Kaabi added that the summit reflects the United Arab Emirates’ transition from supporting the media economy to engineering its operational platforms.

BRIDGE Summit 2026 will bring together leaders across media, technology, investment, and content creation, with a focus on deepening professional engagement to support new business models, co-production, and access to regional and global markets.

Programming will span seven core sectors, namely media, the creator economy, technology and artificial intelligence, marketing, gaming, music, and filmmaking, reflecting key forces reshaping the content landscape.

The inaugural BRIDGE Summit, held in December 2025 at ADNEC, attracted more than 40,000 participants from 182 countries, hosted 1,276 business meetings, and resulted in 48 agreements and partnerships.

-- BERNAMA